Compare Abbott Laboratories (ABT) vs Angi Inc (ANGI) Price & Performance

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

ANGI trades at $4.315, down 5.99% in the last session, reflecting ongoing operational challenges. The stock shows bearish technical signals with support near $4.00 and resistance at $5.00. Recent Q2 2026 earnings missed expectations with a significant EPS loss of $5.70, while revenue declined 11% year-over-year. Despite a low P/E of 14.81 and P/S of 0.19, negative net income margin of -22.35% and ROE of -26.25% highlight profitability struggles. Analyst consensus remains mixed with a $7.00 price target but accelerating pro user churn and legal investigations cloud the outlook.

The outlook for ANGI is cautious due to declining revenue, persistent losses, and competitive pressures. Investment opportunity exists if the company successfully executes its AI pivot and stabilizes user engagement, but risks include ongoing legal probes, high debt, and market share erosion. Near-term volatility is likely amid weak fundamentals and negative sentiment.